Key result
This review summarizes the current status of standardization and quality specifications for cardiac biomarkers, including myoglobin, CK-MB, cardiac troponin I, and natriuretic peptides.
This review highlights the ongoing efforts and current status of standardizing cardiac biomarker assays to optimize their clinical use globally.
Standardization gaps persist for cardiac biomarkers; leaves open need for reference materials to ensure consistent global diagnostics.
Developing primary reference materials to standard cardiac biomarker assays, specifically cardiac troponin I (cTnI) and B-type natriuretic peptide (BNP), as well as develop quality specifications for immunoassays to optimize clinical use, whether for diagnostics or risk assessment, have been primary goals of the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD). The purpose of this paper is to review the current status of standardization issues for myoglobin, creatine kinase MB, cardiac troponin I and natriuretic peptides (BNP and NT-proBNP) and quality specifications for analytical immunoassays for the worldwide, consistent clinical utilization of these and future cardiac biomarkers.
No takes yet. Share an insight, caveat, or question.
Fred S. Apple (2005) conducted a review in Cardiac biomarkers. This review summarizes the current status of standardization and quality specifications for cardiac biomarkers, including myoglobin, CK-MB, cardiac troponin I, and natriuretic peptides.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: